289 related articles for article (PubMed ID: 34735669)
1. New Directions in Imaging Neuroendocrine Neoplasms.
Refardt J; Hofland J; Wild D; Christ E
Curr Oncol Rep; 2021 Nov; 23(12):143. PubMed ID: 34735669
[TBL] [Abstract][Full Text] [Related]
2. Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.
Refardt J; Hofland J; Kwadwo A; Nicolas GP; Rottenburger C; Fani M; Wild D; Christ E
Rev Endocr Metab Disord; 2021 Sep; 22(3):581-594. PubMed ID: 32495250
[TBL] [Abstract][Full Text] [Related]
3. Molecular Imaging of Neuroendocrine Neoplasms.
Refardt J; Hofland J; Wild D; Christ E
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2662-e2670. PubMed ID: 35380158
[TBL] [Abstract][Full Text] [Related]
4. Molecular Imaging in neuroendocrine neoplasias.
Christ E; Wild D; Refardt J
Presse Med; 2022 Jun; 51(2):104115. PubMed ID: 35131317
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
Behr TM; Béhé M; Becker W
Q J Nucl Med; 1999 Sep; 43(3):268-80. PubMed ID: 10568142
[TBL] [Abstract][Full Text] [Related]
6. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
[TBL] [Abstract][Full Text] [Related]
7. Imaging tumors with peptide-based radioligands.
Behr TM; Gotthardt M; Barth A; Béhé M
Q J Nucl Med; 2001 Jun; 45(2):189-200. PubMed ID: 11476170
[TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract][Full Text] [Related]
9. Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.
Fani M; Peitl PK; Velikyan I
Pharmaceuticals (Basel); 2017 Mar; 10(1):. PubMed ID: 28295000
[No Abstract] [Full Text] [Related]
10. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
11. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.
Reubi JC; Waser B
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):781-93. PubMed ID: 12707737
[TBL] [Abstract][Full Text] [Related]
12. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy.
Hu Y; Ye Z; Wang F; Qin Y; Xu X; Yu X; Ji S
Front Endocrinol (Lausanne); 2021; 12():679000. PubMed ID: 34093445
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
14. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
15. [
Giovannini E; Giovacchini G; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Ciarmiello A
Curr Radiopharm; 2019; 12(1):11-22. PubMed ID: 30539709
[TBL] [Abstract][Full Text] [Related]
16. Current status and perspectives in peptide receptor radiation therapy.
Ansquer C; Kraeber-Bodéré F; Chatal JF
Curr Pharm Des; 2009; 15(21):2453-62. PubMed ID: 19601842
[TBL] [Abstract][Full Text] [Related]
17. Advances in the Diagnosis of Neuroendocrine Neoplasms.
Kulkarni HR; Singh A; Baum RP
Semin Nucl Med; 2016 Sep; 46(5):395-404. PubMed ID: 27553465
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging for neuroendocrine tumours.
Antwi K; Nicolas G; Wild D; Christ E
Swiss Med Wkly; 2019 Feb; 149():w20017. PubMed ID: 30852831
[TBL] [Abstract][Full Text] [Related]
19. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
20. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]